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Medullary cystic kidney disease/familial juvenile hyper-
uricemic nephropathy (MCKD/FJHN) are autosomal dom-
inant renal disorders characterized by tubulo-interstitial
fibrosis, hyperuricemia and medullary cysts. They are
caused by mutations in the gene encoding uromodulin,
the most abundant protein in urine. Uromodulin (or
Tamm–Horsfall protein) is a glycoprotein that is exclu-
sively expressed by epithelial tubular cells of the thick
ascending limb of Henle’s loop and distal convoluted
tubule. To date, 37 different uromodulin mutations have
beendescribed inpatientswithMCKD/FJHN. Interestingly,
60% of them involve one of the 48 conserved cysteine
residues.Wehavepreviouslyshownthatcysteine-affecting
mutations could lead to partial endoplasmic reticulum (ER)
retention. In this study, as a further step in understanding
uromodulin biology in health and disease, we provide the
first extensive study of intracellular trafficking and sub-
cellular localization of wild-type and mutant uromodulin
isoforms. We analyzed a set of 12 different uromodulin
mutations that were representative of the different kind
of mutations identified so far by different experimental
approaches (immunofluorescence, electron microscopy,
biochemistry and in vivo imaging) in transiently trans-
fected HEK293 and Madin–Darby canine kidney cells. We
assessed protein processing in the secretory pathway
and could demonstrate that although to different extent,
all uromodulin mutations lead to defective ER to Golgi
protein transport, suggesting a common pathogenetic
mechanism in MCKD/FJHN.
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Uromodulin is the most abundant protein in human urine
under physiological conditions, being excreted at a rate of
50–100 mg per day (1). It was initially characterized by
Tamm and Horsfall in 1950 (2), and it is also referred to
as Tamm–Horsfall protein. Uromodulin is found in urine
as a high-molecular-weight polymer (Mr 1–10  106) that
can be dissociated into monomers of about 95 kDa (3).
It is a glycoprotein with seven out of eight potential N-
glycosylation sites being glycosylated; N-glycans account
for about 25% of its molecular weight (4). Uromodulin is
exclusively detected in epithelial cells of the thick ascend-
ing limb (TAL) of the loop of Henle and in distal convoluted
tubules (DCT) (1). It is membrane bound via a glycosyl
phosphatidylinositol (GPI) anchor, and it is released into the
tubular lumen from kidney tubular cells through a proteo-
lytic cleavage by a yet to be identified protease (5). GPI-
anchored uromodulin is mainly localized at the apical
plasma membrane of epithelial tubular cells (6).
Despite being extensively studied in the past 50 years,
uromodulin biological function has not been fully eluci-
dated. Based on its specific localization in the TAL and
DCT, the ‘diluting’ tracts of the nephron and its ability to
polymerize in vitro to form a gel-like structure that is
water impermeable and allows ion movement (7), it has
been proposed that uromodulin has a role in salt transport
and is important for water impermeability of the TAL,
a process that is crucial for urine concentration. Recent
results demonstrated that urinary uromodulin has a pro-
tective role against urinary tract infections and nephroli-
thiasis. In particular, umod knock-out mice have been
shown to be more susceptible to infections by type 1
fimbriated Escherichia coli (8,9), Klebsiella pneumoniae
and Staphylococcus saprophyticus (10). Furthermore,
umod/ mice show spontaneous formation of calcium
crystals in the kidney that is dramatically increased after
a diet supplemented with ethylene glycol, an oxalate
precursor, and vitamin D3, which enhances calcium
absorption (11). Moreover, uromodulin can directly acti-
vate dendritic cells via the Toll-like receptor-4 pathway
(12), suggesting that this protein may play an important
role in innate immune response in the kidney (13).
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Mutations in uromodulin gene UMOD cause medullary
cystic kidney disease (MCKD) and familial juvenile hyper-
uricemic nephropathy (FJHN), two autosomal dominant
diseases characterized by alteration of urinary concentrat-
ing ability, tubulo-interstitial fibrosis, hyperuricemia and
gout and progressive kidney failure frequently leading to
end-stage renal disease and dialysis (14). Furthermore,
two mutations have been described in patients affected by
glomerulocystic kidney disease (GCKD) (15,16), character-
ized by cyst dilatation and collapse of glomeruli. Including
the new mutation here described, 38 UMOD mutations
have been reported (14–25); the majority of them are
clustered in exons 4 and 5 and localized in the N-terminal
half of the protein. The vast majority of the reported
mutations (35) are missense changes mainly affecting
(more than 50% of the cases) one the 48 conserved
cysteine residues. The remaining three mutations are in-
frame deletions extending from 5 to 33 amino acids.
We have previously reported a preliminary functional study
of four cysteine-affecting uromodulin mutations (C148W,
C150S, C315R and C317Y), showing that mutant protein
trafficking to the cell plasma membrane was impaired in
transiently transfected HEK293 due to partial endoplasmic
reticulum (ER) retention (15). These results were consis-
tent with immunohistochemistry on patient’s kidney bi-
opsies, showing the presence of intracellular uromodulin
aggregates (15,19), and with Western blot analysis of
urinary protein, demonstrating a dramatic uromodulin
reduction in patient urine.
In this study, as a further step in understanding uromodulin
biology in health and disease, we provide the first exten-
sive study of intracellular trafficking and subcellular local-
ization of wild-type (wt) and mutant isoforms. We analyzed
a set of different uromodulin mutations that were repre-
sentative of the different kind of mutations identified so far
by transiently transfecting two kidney cell lines and using
different experimental approaches [immunofluorescence,
electron microscopy (EM), biochemistry and live imaging].
We could demonstrate that mutant uromodulin trafficking
is impaired in all the mutants studied, showing ER to Golgi
trafficking delay although different mutations affect traf-
ficking to different extents.
Results
Uromodulin mutations alter protein trafficking to
the plasma membrane
Uromodulin contains a N-terminal signal peptide, three
epidermal growth factor (EGF)-like domains between
positions 31 and 148 and a fourth potential EGF-like
domain at positions 281–336, a central domain of unknown
function containing eight conserved cysteine residues
(D8C) at positions 171–276 (26), a zona pellucida (ZP)
domain from amino acids 336 to 585 and a GPI anchor
attachment site at position 614 (Figure 1A). EGF-like
domains are almost invariably found in a variety of secreted
proteins or in the extracellular domain of membrane-bound
proteins and are likely involved in protein–protein interac-
tions. The ZP domain is responsible for protein polymer-
ization into 10–15 nm fibers (27).
Among the 38 UMOD mutations reported so far, we
focused on missense mutations identified in families with
MCKD/FJHN and GCKD. This study includes a newly
identified mutation (P236R, 707C>G) that was found in
the affected members of a FJHN Italian family (Brugnano
and Scolari, personal communication). A mutation at the
same nucleotide (707C>T), resulting in the same proline
residue being exchanged for a leucine (P236L), was pre-
viously reported (22). The 12 analyzed mutations (high-
lighted in Figure 1A) are localized in the EGF-like domains
[D59A(19), N128S(18), C148W(15), C315R(15) and
C317Y(15)], in the central portion of the protein
[C150S(15)], including the D8C domain [R204G(19),
C217R(14), T225K(21), M229R(20) and P236R], or in the
ZP domain [C347G (23)].
All the studied mutations are predicted to affect protein
stability when analyzed with different prediction programs
[SIFT (28), PMUT (29) and MUPRO (30)] although to different
extents (Figure 1C).
To assess the effect of different uromodulin mutations on
protein trafficking, we performed transient transfection
experiments in HEK293 cells that do not express uromo-
dulin. We transfected equal amounts of constructs and
verified equal transfection efficiency by cotransfection
with an enhanced green fluorescent protein (EGFP)-
expressing plasmid. Equal amount of total uromodulin
produced in mutant and wt transfected cells was verified
by Western blot analysis (Figure S1). We quantified the
number of transfected cells exposing uromodulin on the
plasma membrane by fluorescent-activated cell sorter
(FACS) analysis 14 h after transfection. Interestingly, the
majority of mutants showed a reduction in the number of
positive cells, suggesting that mutations lead to a delay of
uromodulin transport to the plasma membrane although
this effect varied from a 25% reduction in M229R to a 75%
one in N128S (Figure 1B). The same effect could be
obtained in wt transfected cells that were cultured in
reducing conditions (DTT, 1 and 2 mM). Mutants T225K,
C317Y and C347G did not significantly differ from the wt at
this time-point after transfection. However, a reduction in
the number of positive cells could be observed for these
mutants at shorter time (4 and 6 h) after transfection (data
not shown). Moreover, these mutants revealed a traffick-
ing defect when studied by other experimental approaches
(see below).
Mutant uromodulin is retained in the ER
To assess if trafficking impairment of the different uromo-
dulin mutant isoforms was due to ER retention, as already
demonstrated for the cysteine-affecting mutants, we
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analyzed the intracellular distribution of wt and mutant
uromodulin in transiently transfected HEK293 cells at
different times after transfection. We carried out immuno-
fluorescence analysis on permeabilized cells at 4 and 6 h
after transfection. In wt transfected cells, intracellular
uromodulin signal was mainly localized in the Golgi appar-
atus as shown by colocalization with giantin (Figure 2). On
the contrary, mutant isoforms showed an intracellular
reticular-like staining that mainly colocalized with calreti-
culin, an ER resident protein (Figures 2, S2A,B and S3A,B).
These results suggest that all uromodulin mutations that
were studied lead to defective trafficking of mutant protein
to the plasma membrane due to ER retention. Consis-
tently, uromodulin plasma membrane signal was reduced
in mutant transfected cells (Figure S4). Besides this
common effect, some mutations show a more severe
cellular phenotype than others. For this reason, we
selected for the experiments that are reported hereafter
a subset of representative mutations affecting protein
traff icking to different extent (C150S>T225K>
C347G). To better quantify the difference in intracellular
protein distribution that was observed in immunofluo-
rescence experiments, we carried out EM analysis on
transiently transfected cells 6 h after transfection and as-
sessed the distribution of uromodulin in different cell com-
partments (Figure 3). Wt protein was mainly localized
at the plasma membrane (60%); intracellular protein was
predominantly found in the Golgi apparatus stacks (30%).
On the contrary, the vast majority of mutant protein
(C150S and T225K mutants in Figure 3) was detected in
the ER (75% and 85%, respectively), whereas only a minor
fraction (about 4% in both mutants) was localized at the
plasma membrane. This effect could also be observed for
mutant C347G although to a minor extent (Figure 3).
Figure 1: Fluorescence-activated cell sorter analysis of uromodulin-positive HEK293 cells transiently transfectedwith eitherwild
type or mutant uromodulin isoforms. A) Schematic representation of uromodulin domain organization. Leader peptide is shown as
a dotted box and EGF-like domains are shown as numbered white boxes. Positions of the D8C domain, ZP domain and the GPI-anchor
attachment site are indicated. The seven glycosylation sites are marked as Y. The position and description of the 12 uromodulin mutations
that were analyzed in this study are shown. B) FACS analysis of HEK293 cells transfected with either wt or mutant constructs and positive
for membrane-bound uromodulin on the cell surface. Cells were collected 14 h after transfection. Data are normalized for transfection
efficiency (by cotransfecting with an EGFP-expressing plasmid) and to wt. Average percentage values for five replicates are shown. *, p <
0.05; **, p < 0.01 (Mann–Whitney two-tailed test). Bars represent SD. C) Results of the predicted effect of uromodulin mutations as
assessed by using SIFT, MUPRO and PMUT programs. Scores in each column are relative to themutation indicated above. For SIFT analysis,
scores below 0.05 are predicted to be deleterious. In MUPRO analysis, the predicted relative stability change DDG is given; a negative value
predicts that the mutation is destabilizing. For PMUT analysis, pathological (P) and neutral (N) predicted effects are indicated; statistically
significant scores (confidence index above 5, in a range from 0 to 9) are in upper case. For all programs, scores predicting a pathological
effect are in red and permissive ones are in green.
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We assessed by fluorescence recovery after photobleach-
ing (FRAP) experiments if the defective trafficking of
mutant protein was indeed caused by delayed exit from
the ER or/and by defective protein transport from the trans
Golgi network (TGN) to the plasma membrane. Madin–
Darby canine kidney (MDCK) cells were transiently trans-
fected with wt and mutant EGFP-fused uromodulin con-
structs. We verified that EGFP fusion did not significantly
alter trafficking properties of uromodulin isoforms by
immunofluorescence andWestern blot (by checking ratios
of mature versus precursor protein in soluble and insoluble
fractions) experiments (data not shown). FRAP studies
revealed that mutant transfected cells (C150S and C347G
shown in Figures 4 and 5) showed a significantly reduced
total fluorescence recovery (35% and 54%, respectively)
in the Golgi area 20 min after photobleaching when
compared with wt (81%) (Figures 4 and 5; Movies S1–
3). By using the same experimental approach, no TGN to
plasma membrane trafficking defect could be observed in
mutant transfected cells when compared with wt (Figure 6;
Movies S4–6). The decreased fluorescence recovery at the
Golgi after photobleaching demonstrates that defective
trafficking ofmutant uromodulin isoforms is due to a delayed
exit from the ER.
Transport of uromodulin mutants through the Golgi
apparatus is not impaired
To assess if uromodulin mutations could also affect protein
transit through the Golgi, thereby altering protein glycosyl-
ation and the ratio of immature to mature protein, we
carried out Western blot analyses on transiently trans-
fected HEK293 cells. Uromodulin is present as a precursor
form of 85 kDa and a mature form of about 100 kDa. In wt
transfected cells, the two bands are similarly distributed in
the soluble fraction, whereas the 100-kDa band is greatly
enriched in the insoluble fraction (Figure 7A). On the
contrary, all mutants (Figures 7A and S1) are enriched
both in the soluble and in the insoluble fraction in the low-
molecular-weight band. To assess the oligosaccharide
modifications of the two uromodulin isoforms, cell lysates
were treated with two deglycosidases, endo-b-N-acetyl-
glucosaminidase H (Endo H) and peptide-N-glycosidase F
(PNGase F). While PNGase F can hydrolyze all types of N-
linked glycans of glycoproteins, Endo H cleaves only high-
mannose oligosaccharides of ER glycoproteins, but it does
not cleave Golgi-modified glycoproteins. PNGase F cleaves
both uromodulin isoforms to a 60 kDa one, which corre-
sponds to the deglycosylated protein. On the contrary,
Endo H cleaves the 85 kDa form only (Figure 7B,C),
thereby indicating that it corresponds to an uromodulin
precursor in the ER. These results are consistent with ER
retention of mutant uromodulin. Moreover, the different
ratio of immature to mature form of protein in the soluble
fraction is consistent with the different extent of trafficking
impairment for the studied mutations that was observed
by other experimental approaches.
Transiently transfected HEK293 cells were treated with
Phosphatidylinositol-specific phospholipase C (Pi-PLC),
a lipase that hydrolyzes the phosphate bond in the GPI
anchor, therefore releasing GPI-anchored membrane pro-
teins from the cell surface, before preparing protein
extracts (Figure 8A). Both wt and mutant protein are
cleaved by Pi-PLC, suggesting that mutations do not affect
uromodulin GPI anchoring. Most of the proteins that are
released by Pi-PLC treatment correspond to the 100-kDa
mature form present in the insoluble fraction. Endo H and
Figure 2: Immunofluorescence analysis showing intracellular distribution of wt and mutant uromodulin in transiently trans-
fected HEK293 cells. Cells were transfected, methanol fixed 6 h after transfection and incubated with anti-uromodulin and either anti-
giantin (Golgi marker) or anti-calreticulin (ER marker) antibodies. Wt uromodulin is mainly localized to the Golgi apparatus, while mutant
protein is mainly localized in the ER. Bar ¼ 35 mm.
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PNGase F assays clearly show that both wt and mutant Pi-
PLC-released uromodulin isoforms are fully glycosylated
(Figure 8B), suggesting that uromodulin mutations do not
alter protein modification in the Golgi apparatus. The same
result could be obtained when analyzing wt and mutant
protein released in the culture medium (data not shown).
Discussion
This study provides the first extensive functional analysis
on 12 different uromodulin mutations, showing for the
first time that different mutations lead to a common traf-
ficking defect of the mutated protein, thereby suggesting
Figure 3: Immuno-EM analysis of HEK293 cells transiently transfected with either wt or mutant uromodulin isoforms. Cells were
fixed 6 h after transfection. Quantification of gold particles residing within different compartments of the secretory pathway is shown. While
wt uromodulin is mainly on the plasma membrane and in the Golgi, most of mutant proteins are retained in the ER. Bars represent SD.
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a common pathogenetic mechanism in uromodulin stor-
age diseases.
Including the new mutation P236R described here, 38
different UMOD mutations have been reported so far in
families with MCKD/FJHN and GCKD, comprising 35 mis-
sense mutations and three in-frame deletions. Interest-
ingly, more than half of the mutations (21) affect one of the
48 conserved cysteine residues that are believed to be
engaged in the formation of 24 intramolecular disulphide
bonds (31). Cysteine-affecting mutations are therefore
likely to alter disulphide bonds pattern and hence protein
structure. Other mutations that could affect protein folding
are: G103C, V93_G97del4ins, E188del33, changes that
likely affect the disulfide bond pattern by inserting/deleting
cysteine residues and N128S, which is predicted to be part
of the calcium co-ordinating site in EGF-like domain III (18).
Indeed, by affecting calcium binding, this mutation could
destabilize the EGF-like domain conformation and increase
interdomain flexibility (32). The effect of the other reported
mutations is more difficult to be predicted.
To assess if different mutations in uromodulin could lead to
a common effect on protein intracellular trafficking, we
studied a panel of mutations that are representative of the
different UMOD mutations known so far. In particular, we
chose mutations that are localized in the EGF-like domains
(D59A, N128S, C148W), including putative EGF-like IV
(C315R, C317Y), in the central part of the protein
(C150S), comprising the D8C domain (R204G, C217R,
T225K, M229R and P236R), or in the ZP domain
(C347G). All mutations but one (D59A) affect amino acid
residues that are conserved in the mouse, rat, dog and
Figure 4: Time-lapse imaging of MDCK cells transiently transfected with either wt or mutant EGFP–uromodulin constructs.
FRAP in the Golgi apparatus region is shown (arrowheads).
Figure 5: FRAP in the Golgi apparatus area in MDCK cells
transiently transfected with either wt or mutant EGFP–
uromodulin constructs. Average fluorescence intensities within
the region of interest are shown (time-points every 5 seconds).
Although to different extent, uromodulin mutants show a signifi-
cant reduction in the fluorescence recovery, suggesting an ER to
Golgi trafficking defect.
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cow uromodulin homologues, aspartic acid 59 being
replaced by a serine in the cow sequence.
We assessed the effect of mutations by three different
programs, SIFT (28), PMUT (29) and MUPRO (30), that
allow accurate prediction in the absence of protein
tertiary structure information. Although to different
extent, all the analyzed mutations were predicted to
destabilize the protein structure by at least one of the
programs.
A common effect on protein trafficking could be clearly
detected for all the mutations we investigated. By using
FACS analysis, immunofluorescence and biochemical
characterization, we were able to demonstrate partial
retention in the ER of the mutant protein. Interestingly,
different mutations seemed to impair protein trafficking
to different extents. This difference was evident in
several experiments, as shown, for instance, for mutants
C150S and C347G (Figures 1B, 4–6), the former leading
to a more severe cellular phenotype. Based on that, for
some of the experimental conditions, we focused onto
a subset of mutations that were representative of the
different cellular phenotype severity. These results might
reflect different in vivo effects of uromodulin mutations
as already observed for other disease-associated pro-
teins, e.g. podocin (33). However, based on the published
clinical data of patients carrying the analyzed mutations,
no clear phenotype to genotype correlation could be
established.
Figure 6: Time-lapse imaging of
MDCK cells transiently trans-
fected with either wt or mutant
EGFP–uromodulin constructs.
FRAP of the plasma membrane
area is shown. Areas of photo-
bleaching are indicated by the red
dashed line. The graph below
shows average fluorescence inten-
sities in the region of interest after
photobleaching (time-points every 5
seconds). Uromodulin mutations do
not seem to alter TGN to plasma
membrane trafficking.
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Our results on wt uromodulin trafficking are consistent
with previously published ones. In transiently transfected
cells, the intracellular distribution of the protein was mainly
localized in the Golgi, as clearly measured in EM experi-
ments (Figure 3). This is consistent with previous findings
in stably transfected HeLa cells, showing that intracellular
[3H]mannose-labelled uromodulin was mainly separated
as di- and trisialylated glycopeptides, suggesting that the
protein accumulates in the distal Golgi compartments
before being exposed at the cell surface (34).
A trafficking defect of mutant isoforms is consistent with
previously published results, showing the presence of
intracellular uromodulin aggregates in kidney biopsies from
five patients (15,19), three of them carrying missense
mutations not affecting cysteine residues. This finding
underlies an early event in the disease progression, and
it does not seem to be a mere consequence of advanced
renal failure, as it was also reported in a patient first in his
adolescence with a mild renal insufficiency (24). Uromo-
dulin intracellular retention is also consistent with a dra-
matic reduction of protein levels in patient urine (15,19,35).
Reduced protein excretion does not seem to be correlated
to gender, age or glomerular filtration rate and seems to
exceed the 50% expected one in the case of a heterozy-
gous mutation, suggesting a possible dominant negative
effect of mutant uromodulin in the tubule cells. However,
no clear detrimental effect on wt protein trafficking could
be observed when simulating the heterozygous state by
transiently cotransfecting wt and mutant isoforms (15).
Nonetheless, we cannot exclude that a dominant negative
mechanism might require prolonged expression, i.e.
expression of the two alleles in stably transfected cells.
Previous mass spectrometry experiments have shown
that only wt uromodulin could be detected in urine
samples from patients with established chronic renal
failure (19), suggesting that mutant protein is entirely
retained in tubular epithelial cells. Our results in transiently
transfected HEK293 and MDCK cells are partly in contrast
with these observations. Although differences between
wt andmutant transfected cells can be appreciated with all
the different experimental approaches that we undertook,
we neither observed full retention of the mutant protein in
the ER nor the formation of intracellular aggregates, as
could be ascertained by immunofluorescence and EM
analyses. Indeed, mutant protein isoforms could reach
the plasmamembrane and could be detected in the culture
medium. Similar results were previously reported in stably
transfected HEK293 and thick ascending limb of Henle’s
loop (TALH) cells where mutant uromodulin was trans-
ferred to the plasma membrane and released into the
culture medium although less efficiently than the wt pro-
tein (36). These findings could reflect biases introduced by
the in vitro systems, as high expression levels of the
protein might saturate chaperone activity in the ER and the
use of cell lines possibly having different secretory capac-
ity compared with renal epithelial cells expressing uromo-
dulin. However, we cannot exclude that mutant
uromodulin could be detected when analyzing urine sam-
ples from presymptomatic patients with little, if any,
impairment of renal function.
For the first time, we show that defective trafficking of
mutant uromodulin is due to ER retention while protein GPI
anchoring in the ER is not affected. Moreover, FRAP
experiments showed that the export dynamics from the
trans Golgi compartment to the plasma membrane is not
affected. Indeed, uromodulin mutations did not seem to
alter the glycosylation processes in the Golgi because Pi-
PLC-purified and medium-purified mutant proteins that
were treated with deglycosidases did not show any size
difference when compared with the wt one. Of course,
qualitative changes at a single N-glycan in mutant uromo-
dulin cannot be excluded, andmore in-depth studies would
be needed to address this point.
Retention of the mutant uromodulin in the ER is very likely
due to a common detrimental effect of mutations on
protein tertiary structure and represents a key step in the
Figure 7: Western blot detection of wild type and mutant
uromodulin in extracts of transiently transfected HEK293
cells. A) Western blot detection of uromodulin in the soluble (L)
and insoluble (P) fractions of RIPA buffer extracts from tran-
siently transfected HEK293 cells expressing either wt or mutant
uromodulin. Uromodulin is found as a 100- and an 80-kDa
isoform, corresponding to the mature (M) and a precursor (P)
protein. B and C) Deglycosylation of uromodulin isoform. Cell
extracts from wt and mutant uromodulin transfected cells
were treated with endo-b-N-acetylglucosaminidase H (Endo H)
(B) or peptide-N-glycosidase F (PNGase F) (C) and changes in
molecular weight were visualized by Western blot. The 80-kDa
uromodulin only is cleaved by Endo H to an about 60-kDa
deglycosylated (D) isoforms. These data indicate that the 80-
kDa isoform is an ER precursor that is enriched in the mutant
transfected cell lysates.
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pathogenesis of uromodulin-associated diseases. ER
retention of misfolded mutant proteins has been described
in several diseases (37,38), including kidney-affecting
ones, as for aquaporin-2 in nephrogenic diabetes insipidus
(39) and podocin in steroid-resistant nephrotic syndrome
(33). In some cases, retained mutant protein is eventually
retrotraslocated to the cytoplasm and degraded. However,
in other conditions, the mutant protein can form aggre-
gates that are accumulated either in the ER or in the
cytoplasm (40). Perturbation of ER function can eventually
lead to ER stress and activation of the unfolded protein
response (UPR) pathway, a complex signalling network
that upregulates ER chaperones and foldases and de-
creases the biosynthetic burden of the secretory pathway
by downregulating expression of genes encoding secreted
proteins (41). Alternatively, overload of the ER with mutant
protein could activate the ER overload response (EOR),
leading to activation of the nuclear transcription factor
NFkB (42,43). Sustained activation of either EOR or UPR
can eventually lead to cell death (44,45). It has been
previously demonstrated that stable expression of two
mutant uromodulin isoforms (H177–185del and C148Y) in
HEK293 and TALH cells was associated to decreased
protein secretion and increased apoptosis rate, particularly
when cells were cultured in serum-free medium (36). This
effect was partly rescued by treatment with colchicine and
sodium 4-phenylbutyrate.
Cell response pathways that are elicited by mutant uro-
modulin retention are presently not known. Further experi-
ments will be needed to characterize the toxicity of mutant
protein expression in cell models and to understand its
significance in vivo. It seems reasonable to hypothesize
that accumulation of mutant uromodulin could lead to ER-
stress-induced renal tubular cell death, eventually damaging
kidney function and resulting in progressive renal failure.
In summary, we have reported a functional study of a panel
of different uromodulin missense mutations characterizing
protein processing in the secretory pathway. We showed
that all mutations lead to trafficking defects due to
retention in the ER. Mutant protein GPI anchoring to the
membrane, modifications in the Golgi and TGN to plasma
membrane transport were not affected. These data point
at ER retention as a key event in the pathogenesis of
uromodulin-associated diseases.
Materials and Methods
Uromodulin expression constructs and site-directed
mutagenesis
Uromodulin full-length complementary DNA (cDNA) was cloned into the
expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) as previously
described (15). Mutations in the uromodulin cDNA were introduced by the
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
Figure 8: Western blot detection of
wild type and mutant uromodulin
after Pi-PLC treatment of transiently
transfected HEK293 cells. A) Western
blot detection of uromodulin in the
soluble (L) and insoluble (P) fractions
of RIPA buffer extracts from transiently
transfected HEK293 cells expressing
either wt or mutant uromodulin. In
lanes marked with a þ, cells were
treated with Pi-PLC prior to cell extract
preparation. Quantification of the ratio of
mature (grey) to precursor (white) bands
is shown below each lane. Pi-PLC
treatment releases membrane-bound
uromodulin both in wt and in mutant-
expressing cells, suggesting that muta-
tions do not alter GPI anchoring. Alpha-
tubulin expression is shown as a loading
control. B) Western blot analysis of Pi-
PLC-cleaved uromodulin from wt and
mutant transfected cells. Treatment
with Endo H and PNGase F shows that
Pi-PLC-cleaved wt and mutant uromo-
dulin are of the mature type only. Un,
untrasfected HEK293 cells.
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We introduced the following mutations: 176A>T (codon GAT>GCT, D59A),
383A>G (codon AAT>AGT, N128S), 610C>G (codon CGC>GGC, R204G),
649T>C (codon TGC>CGC, C217R), 674C>A (codon ACG>AAG, T225K),
686T>G (codon ATG>AGG, M229R) and 707C>G (codon CCG>CGG,
P236R) (Base number 1 corresponds to the first base of the translation
start codon, AC NM_003361). The primer pairs used for site-directed
mutagenesis are listed below (50 to 30):
• D59Af – GGGCTTCACCGGCGCTGGCCTGACCTGCGT
• D59Ar – ACGCAGGTCAGGCCAGCGCCGGTGAAGCCC
• N128Sf – CTGGCCACATGTGTCAGTGTGGTGGGCAGCTAC
• N128Sr – GTAGCTGCCCACCACACTGACACATGTGGCCAG
• R204Gf – CTGCGCGGCTGGTACGGCTTCGTGGGCCAGG
• R204Gr – CCTGGCCCACGAAGCAGTACCAGCCGCGCAG
• C217Rf – CGCATGGCCGAGACCCGCGTGCCAGTCCTGC
• C217Rr – GCAGGACTGGCACGCGGGTCTCGGCCATGCG
• T225Kf – TCCTGCGCTGCAACAAGGCCGCCCCCATGTG
• T225Kr – CACATGGGGGCGGCCTTGTTGCAGCGCAGGA
• M229Rf – ACACGGCCGCCCCCAGGTGGCTCAATGGCAC
• M229Rr – GTGCCATTGAGCCACCTGGGGGCGGCCGTGT
• P236Rf – GGCTCAATGGCACGCATCGGTCCAGCGACGAGGG
• P236Rr – CCCTCGTCGCTGGACCGATGCGTGCCATTGAGCC
Primers for site-directed mutagenesis for the mutations C148W, C150S,
C315R, C317Y and C347G were previously published (15,23).
Uromodulin–EGFP fusion construct was obtained by amplifying EGFP cDNA
with primers (EGFP-f, CTACCGGTGGTGTGAGCAAGGGCGAGGAGC;
EGFP-r, CTACCGGTCTTGTACAGCTCGTCCATG). EGFP was then inserted
into a newly created AgeI site at position 78 in the uromodulin cDNA. The
tag is inserted between threonine 26 and serine 27 in the protein sequence.
Constructs were fully resequenced before transfection experiments.
Newly reported mutation P236R was found in seven affected members of
a FJHN Italian family (Brugnano and Scolari, personal communication).
Cell sorting experiments
Cell sorting experiments were carried out as previously reported (15).
Briefly, transfections were carried out by Metafectene (Biontex, Munich,
Germany) according to the manufacturer’s instructions. We used 1 mg of
plasmid DNA for 2.6 106 cells. Transfection efficiency was determined by
cotransfecting with EGFP-expressing vector pcDNA3x(þ)MyEGFP (Invitro-
gen). We changed media 2 h after transfection and let cells grow for 6–12 h.
For cells cultured in reducing conditions, added media contained 1/2 mM
DTT. Cells were collected in Versene (Invitrogen, USA) and resuspended in
aMEM þ FBS 2% (2.4  106 cells/mL). Cells were incubated with goat
polyclonal antibody anti-uromodulin (1:1000/700 000 cells; ICN Biomed-
icals, Irvine, CA, USA) for 30 min at 48C and washed with aMEM þ FBS
2%. Cells were incubated for 30 min at 48C with the secondary antibody:
polyclonal donkey anti-goat antibody conjugated with Alexa 488 (1:2500/
700.000 cells; Molecular Probes, Invitrogen, Carlsbad, CA, USA). Cells
were washed with aMEM þ FBS 2%, resuspended in 300 mL of aMEM þ
FBS 2% and incubated for 10 min at room temperature with 7-amino-
actinomycin D for the exclusion of nonviable cells. Cell fluorescence was
measured by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA,
USA) and analyzed by CELLQUEST software (BD Biosciences). Equal
amount of total uromodulin produced in mutant and wt transfected cells
was verified by Western blot analysis. Transfected cells were lysed 14 h
after transfection in RadioImmunoPrecipitation Assay (RIPA) buffer [1%
(Octylphenoxy)polyethoxyethanol (IGEPAL CA-630); Sigma-Aldrich, 50 mM
Tris pH 7.4, 150 mM NaCl, 0.5% deoxycholate (DOC), 0.1% SDS, 2 mM
ethylenediaminetetraacetic acid (EDTA), 0.5 mM phenylmethylsulphonyl
fluoride (PMSF)]. Equal amount of protein (40 mg) was loaded onto reducing
8% SDS–PAGE. Western blot for uromodulin and alpha-tubulin was carried
out as described below. Transfection efficiency was assessed by loading
equal amount of protein extracts (30 mg) onto reducing 10% SDS–PAGE
and by incubating transblotted PVDF membrane (Millipore, Billerica, MA,
USA) with rabbit polyclonal antibody against green fluorescent protein
(1:2000 dilution; Molecular Probes; Invitrogen) followed by incubation with
horseradish-peroxidase-conjugated secondary antibody (1:5000 dilution;
Promega, Madison, WI, USA).
Immunofluorescence experiments
Cells were grown for 16 h prior to transfection on glass cover slips in 12-well
plates (Corning Life Sciences, Corning, NY, USA). Transfectionswere carried
out as above using 500 ng of plasmid DNA for 106 cells. Fresh media were
added 2 h after transfection. Cells were fixed at different times after
transfection (4–6 h) either in 100% methanol for 5 min at 208C (permea-
bilized cells) or in 4% paraformaldehyde (PFA) for 30 min at 378C (un-
permeabilized cells). Unpermeabilized and permeabilized cells were
incubated with preimmune donkey serum for 30 min at 378C. Cells were
then incubated with goat polyclonal primary antibody against uromodulin
(1:500 dilution; ICN Biomedicals). Permeabilized cells were also stained
using sheep anti-giantin (1:300 dilution; Golgi marker; Covance Research
Products, Berkeley, CA, USA) or rabbit anti-calreticulin (1:500 dilution; ER
marker; Nventa, San Diego, CA, USA). We washed cells in phosphate-
buffered saline solution and incubatedwith appropriate secondary antibodies
(1:1000): AlexaFluor-594-conjugated donkey secondary antibody against
goat immunoglobulin G (IgG) (Molecular Probes; Invitrogen) and Alexa-
Fluor-488-conjugated donkey secondary antibody against sheep or rabbit
IgG (Molecular Probes; Invitrogen). Unpermeabilized cells were incubated
with tetramethylrhodamine B isothiocyanate (TRITC)-conjugated lectin
(1:100 dilution; Sigma-Aldrich. We placed cells in fluorescent mounting
medium (DakoCytomation, Glostrup, Denmark) over microscope slides and
visualized them under confocal microscope Leica TCS SP2 AOBS (Leica
Microsystems, Bannockburn, IL, USA).
Immuno-EM analysis
HEK293 cells were transfected using Lipofectamine 2000 (Invitrogen) with
either wt or mutant uromodulin isoforms (500 ng of plasmid DNA for 106
cells), fixed with a mixture of 4% paraformaldehyde and 0.05% glutaralde-
hyde 6–8 h after transfection, labelled with goat polyclonal primary antibody
against uromodulin (ICN Biomedicals) using the gold-enhance protocol,
embedded in Epon-812 and cut as described previously (46). EM images
were acquired from thin sections under a Philips Tecnai-12 electron
microscope (Philips, Eindhoven, The Netherlands) using an ULTRA VIEW
CCD digital camera. Thin sections were also used for quantification of gold
particles residing within different compartments of the secretory pathway.
Time-lapse imaging
Time-lapse images were obtained using a Zeiss LSM510 confocal micro-
scope system (Carl Zeiss, Gottingen, Germany). MDCK cells were trans-
fected using Lipofectamine 2000 (Invitrogen) with either wt or mutant
uromodulin–EGFP constructs (1 mg of plasmid DNA for 106 cells). MDCK
cells expressing uromodulin–EGFP fusion proteins were observed at 378C
in 20mMHEPES-buffered DMEM during the course of observation. For the
ER to Golgi FRAP experiments, cells were analyzed 6 h after transfection.
For the Golgi to plasma membrane FRAP experiments, cells were exposed
to 208C block 24 h after transfection to collect protein in the Golgi stacks.
Fluorescence around the Golgi area was removed by selective photo-
bleaching. Cells were then shifted from 208C to 378C in the presence of
cycloheximide and therefore uromodulin–EGFP was allowed to leave the
Golgi to the plasma membrane. Temperature was controlled with a Nevtek
air stream stage incubator (Nevtek, Burnsville, VA, USA). EGFP molecules
were excited with the 488-nm line of a krypton–argon laser and imaged with
a 505–530 nm bandpass filter. Confocal digital images were collected at
15-second intervals using a Zeiss Plan-Neofluor 63 oil immersion objec-
tive (NA 1.4) with open pinhole to maintain the entire cell within the centre
of the focal depth and thus to minimize changes in fluorescence. Selective
photobleaching in regions of interest within the cell was carried out on the
ZEISS LSM510 using 100 consecutive scans with a 488-nm laser line at full
power. Average fluorescence intensities within regions of interests were
quantified using LSM 3.2 software. The number of analyzed cells in the ER
to Golgi experiments are 10 (wt, C347G) and 8 (C150S). The number of
analyzed cells in the Golgi to plasma membrane experiments are eight
(wt, C150S) and six (C347G).
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Western blot
HEK293 cells transfection was carried out by Metafectene (Biontex)
according to the manufacturer’s instructions. We used 1 mg of plasmid
DNA for 2.6  106 cells. We changed media 2 h after transfection and let
cells grow for 24–48 h. Where indicated, cells were incubated with Pi-PLC
digestion medium (DMEM þ 20 mM Tris–Cl pH 7.4 þ Pi-PLC 0.3 U/mL;
Sigma-Aldrich) for 2 h in a 5% CO2 atmosphere at 378C. Cells were
collected in Versene (Invitrogen) and lysed in RIPA buffer (1% IGEPAL CA-
630; Sigma-Aldrich, 50 mM Tris pH 7.4, 150 mM NaCl, 0.5% DOC, 0.1%
SDS, 2 mM EDTA and 0.5 mM PMSF). Where indicated, cell lysate and Pi-
PLC digestion medium were treated with two different deglycosidases,
peptide-N-glycosidase F (PNGase F; New England Biolabs, Beverly, MA,
USA) and endo-b-N-acetylglucosaminidase H (Endo H; New England
Biolabs) according to the manufacturer’s protocol. Proteins were quantified
by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). We loaded
equal amounts of proteins (25 mg) onto reducing 8% SDS–PAGE. We
incubated transblotted PVDF membranes (Millipore) with goat polyclonal
antibody against uromodulin (1:1000 dilution; ICN Biomedicals) followed by
incubation with horseradish-peroxidase-conjugated secondary antibody
(1:2000 dilution; Promega). Anti-alpha-tubulin mouse monoclonal antibody
was used as a loading control and to exclude cell lysis in the Pi-PLC digestion
medium (1:2500 dilution; Molecular Probes; Invitrogen). Protein bands
were visualized with the enhanced chemiluminescence kit (Amersham
Biosciences, Piscataway, NJ, USA). When needed, quantification of the
relative band intensities on the films was determined using a UVP
ChemiDoc-IT Imaging System (UVP, Upland, CA, USA).
Prediction programs
PMUT (29) is available at http://mmb2.pcb.ub.es:8080/PMut. The effect of
an amino acid substitution is predicted using only sequence-derived
information (secondary structure, accessibility, evolutionary conservation,
structure data and residue properties). All the derived information is input to
a neural network that provides the final prediction on whether the target
mutation is either pathological or neutral. The final output is always (i)
a pathogenicity index ranging from 0 to 1 (indexes >0.5 signal pathological
mutations) and (ii) a confidence index ranging from 0 (low) to 9 (high).
MUPRO (30) (http://www.ics.uci.edu/~baldig/mutation_intro.html) is a set of
machine learning programs to predict how single-site amino acid mutation
affects protein stability. We carried out the prediction of the value of energy
change (DDG) using support vector machine (recommended). If DDG has
a negative sign, a pathological effect of the mutation is predicted.
SIFT (28) (http://blocks.fhcrc.org/sift/SIFT.html) is based on the premise
that protein evolution is correlated to protein function. Positions important
for function should be conserved in an alignment of the protein family,
whereas unimportant positions should appear diverse in an alignment.
Amino acid changes with normalized probabilities less than 0.05 are
predicted to be deleterious; those greater than or equal to 0.05 are
predicted to be tolerated.
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Supplementary Materials
Figure S1: Western blot detection of uromodulin and EGFP in extracts
of transiently transfected cells. A) Western blot analysis of uromodulin in
the soluble (L) and insoluble (P) fractions of RIPA buffer extracts from
HEK293 cells transiently transfected with the EGFP-encoding plasmid
pcDNA3x(þ)MyEGFP and with either wt or mutant uromodulin. Cells were
lysed 14 h after transfection. While the majority of uromodulin is detected
as amature form in the insoluble fraction for the wt, mutants are enriched in
the immature form, mainly in the soluble fraction. Alpha-tubulin is shown as
a loading control. B) Western blot analysis of EGFP as a control of
transfection efficiency. Equal amounts of soluble fractions from (A) were
loaded. Alpha-tubulin is shown as a loading control.
Figure S2: Intracellular distribution of different mutant uromodulin
isoforms and giantin in transiently transfected HEK293 cells. A and B)
Cells were transfected, methanol fixed 6 h after transfection and incubated
with anti-uromodulin and anti-giantin (Golgi marker). Bar ¼ 35 mm.
Figure S3: Intracellular distribution of different mutant uromodulin
isoformsand calreticulin in transiently transfectedHEK293 cells.A and B)
Cells were transfected, methanol fixed 6 h after transfection and incubated
with anti-uromodulin and anti-calreticulin (ER marker). Bar ¼ 35 mm.
Figure S4: Immunofluorescence analysis showing plasma membrane
distribution of wt and mutant uromodulin in transiently transfected
HEK293 cells. Cells were transfected, PFA fixed 6 h after transfection
(unpermeabilized cells) and incubated with anti-uromodulin and lectin-
TRITC that was used to stain the plasma membrane. Bar ¼ 35 mm.
Movie S1: Time-lapse video of MDCK cells expressingwt uromodulin–
EGFP. Confocal digital images were collected at 15-second intervals for a
duration of 20min after selective photobleaching in the Golgi apparatus region.
Movie S2: Time-lapse video of MDCK cells expressing mutant (C150S)
uromodulin–EGFP. Confocal digital images were collected at 15-second
intervals for a duration of 20 min after selective photobleaching in the Golgi
apparatus region.
Movie S3: Time-lapse video of MDCK cells expressingmutant (C347G)
uromodulin–EGFP. Confocal digital images were collected at 15-second
intervals for a duration of 20 min after selective photobleaching in the Golgi
apparatus region.
Movie S4: Time-lapse video of MDCK cells expressingwt uromodulin–
EGFP. Confocal digital images were collected at 15-second intervals for
a duration of 25 min after selective photobleaching in the plasma mem-
brane region.
Movie S5: Time-lapse video of MDCK cells expressing C150S
uromodulin–EGFP. Confocal digital images were collected at 15-second
intervals for a duration of 25 min after selective photobleaching in the
plasma membrane region.
Movie S6: Time-lapse video of MDCK cells expressing C347G
uromodulin–EGFP. Confocal digital images were collected at 15-second
intervals for a duration of 25 min after selective photobleaching in the
plasma membrane region.
Supplemental materials are available as part of the online article at http://
www.blackwell-synergy.com
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